Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | PRF1 | P14222 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | ERN1 | O75460 | 1/20 | 0.57 |
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045506 | 0.94 | PRF1 (0.68) | CD274HPGDPRF1ALDH1A1HTR1A | |
| SCHEMBL14761429 | 0.81 | PRF1 (0.90) | CD274HPGDPRF1 | |
| SCHEMBL2047025 | 0.81 | PRF1 (0.90) | CD274HPGDPRF1 | |
| SCHEMBL14761425 | 0.81 | PRF1 (0.90) | CD274HPGDPRF1 | |
| SCHEMBL1662866 | 0.81 | CD274 (0.71) | CD274HPGDALDH1A1HTR1AMAOA | |
| SCHEMBL2021463 | 0.80 | PRF1 (0.61) | HPGDPRF1ALDH1A1POLBKDM4E | |
| SCHEMBL8167646 | 0.78 | CD274 (1.00) | CD274HPGDALDH1A1HTR1AMAOA | |
| SCHEMBL2018172 | 0.77 | PRF1 (0.63) | PRF1ALDH1A1POLB | |
| SCHEMBL16574185 | 0.77 | CD274 (0.79) | CD274HPGDALDH1A1HTR1AMAOA | |
| SCHEMBL6569882 | 0.77 | CD274 (0.77) | CD274HPGDALDH1A1HTR1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | CD274 386/4885HPGD 677/4885PRF1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.